http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
송상훈(Sang Hoon Song),곽철(Cheol Kwak) 대한비뇨기종양학회 2011 대한비뇨기종양학회지 Vol.9 No.3
The aim of this review is to provide a discussion of the diagnostic evaluation of biochemicalrecurrence following radical prostatectomy (RP) and radiotherapy (RT). Life-long periodic PSA testing for biochemical recurrence is standard of care;however, there is no single definition of biochemicalrecurrence that reliably predicts clinical recurrence. It is recommended that biochemical (PSA) recurrence following radical prostatectomy be defined as a serum PSA of 0.2ng/ml or greater, with a second confirmatory level of PSA of ≥0.2ng/ml. It is important to bear in mind that this in no way is proposed as a threshold value suggestive of initiation of salvage therapy nor a predictor of death from prostate cancer. Once PSA recurrence after RP has been diagnosed, it is important to determine whether the recurrence has developed at local or distant sites because managementof PSA failure is dependent on the site of recurrence. In general, digital rectal examination is not useful in men with undetectable or very low PSA levels. Conventional diagnostic imaging, such as computed tomography (CT) and bone scintigraphy, very often are not able to detect whether the recurrence has developed at local and/or distant (systemic) sites. PSA velocity and the slope of PSA increase seem to be the most important predictors of distant metastases. The definition of PSA recurrence after radiation therapy has also been debated. Currently, although not without controversy, the most commonly used definition was developed by the ASTRO Consensus Panel. This definition requires 3 consecutive increases in PSA after nadir has been reached, with the date of failure being the midpoint between the nadir and the first of 3 consecutive rises. A second ASTRO and the Radiation Therapy Oncology Group Consensus Conference revised the ASTRO definition. The panel recommended a rise by 2ng/ml or more above the nadir PSA be considered the standard definition for biochemical failure after EBRT with or without HT and the date of failure be determined ‘at call’ (not backdated). Follwing RT, diagnostic procedures for PSA relapse such as endorectal MRI is valuable for men who are candidate for radical salvage prostatectomy.
전립선염 증상지수를 이용한 전립선염 증상의 규모와 삶의 질에 미치는 영향
변석수,강대희,유근영,박수경,곽철,조문기,이종욱,김현회,Byun, Seok-Soo,Kang, Dae-Hee,Yoo, Keun-Young,Park, Sue-Kyung,Kwak, Cheol,Jo, Moon-Ki,Lee, Chong-Wook,Kim, Hyeon-Hoe 대한예방의학회 2000 Journal of Preventive Medicine and Public Health Vol.33 No.4
Objectives : To determine the prevalence of prostatitis symptoms in the general population by questionnaire survey and to measure the effect of prostatitis symptoms on quality of life(QOL). Materials & Methods : A cross sectional community-based epidemiologic study was performed on 2,034 men, living in the Seoul metropolitan area using stepwise random sampling. Out of 2,034 interviewees, 1,356 men who were older than 40 and provided sufficient information were selected for this study. The questionnaires were completed by well trained interviewers. Contents of the questionnaires included demographic data, the Prostatitis Symptom Index(PSI), the International Prostate Symptom Score(IPSS), a general health questionnaire section and a sexual health questionnaire section. The PSI was composed of a sum of the scores from three questions about dysuria, penile pain and perineal pain and it ranged 0 to 12. Incidence of prostatitis symptoms was defined by a score of 4 or more and the reference group was defined as consisting of those with a score of 3 or less. The rate of incidence of prostatitis symptoms was assessed according to age and the difference of QOL between the prostatitis symptoms group and the reference group. Results : The overall positive rate of prostatitis symptoms measured by the PSI, in men older than 40, living in the Seoul metropolitan area, was 4.5%(61/1,356), adjusted to 4.8% by the relative proportion of this age group in the general population of the Seoul metropolitan area as compared to Korea and the World. The proportion of the group with prostatitis symptoms assessed by the PSI did not increase with age although the proportion of participants with moderate to severe lower urinary tract symptoms (LUTS) did increase with age. The group with prostatitis symptoms suffered from a much greater incidence of LUTS compared to the reference group (p<0.05). The QOL scores of the IPSS, and the general health and sexual health status of the group with prostatitis symptoms, were worse than those of the reference group.(p<0.05). Conclusions : The positive rate of prostatitis symptoms in men older than 40, living in the Seoul metropolitan area, was 4.8% and it didn't increase with age. The general QOL of the group with prostatitis symptoms was much worse than that of the reference group.
Hyuk-Dal Jung(정혁달),Hyeong Dong Yuk(육형동),Ulanbek Balpukov,Ja Hyeon Ku(구자현),Cheol Kwak(곽철),Hyeon Hoe Kim(김현회),Chang Wook Jeong(정창욱) 대한비뇨기종양학회 2020 대한비뇨기종양학회지 Vol.18 No.3
Purpose: To evaluate the clinical usefulness of the Seoul National University Prostate Cancer Risk Calculator (SNU-PCRC) to reduce unnecessary prostate biopsy and to increase the detection rate of high-risk cancer. Materials and Methods: We retrospectively analyzed 546 patients who underwent prostate biopsy between 2014 and 2016. The subjects were divided into 2 groups based on the type of risk calculator used: conventional and SNU-PCRC group. In the SNU-PCRC group, prostate biopsy was recommended when the probability of SNU-PCRC was more than 30%. Results: The SNU-PCRC group had significantly smaller prostate volume (p=0.010) and significantly more digital rectal examination and transrectal ultrasonography (TRUS) abnormalities (p=0.011 and p=0.010, respectively). Overall detection (71.9% vs. 32.1%) and high-risk cancer detection rates (40.6% vs. 19.3%) were significantly higher in the gray zone (prostate-specific antigen=4-10 ng/mL) (p<0.001 and p=0.006). The group with prostate cancer risk ≥30% on the SNU-PCRC compared to <30% group, overall detection rate of 72.3% versus 30.2% and high-risk detection rate of 60.6% versus 18.3% were significantly different (p<0.001 and p<0.001). Applying the SNU-PCRC to the conventional group could avoid unnecessary prostate biopsy in 50.6%. Conclusions: SNU-PCRC is clinically useful to reduce unnecessary prostate biopsy and increase overall detection rate and high-risk cancer detection rate.